<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255836</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-19-20392</org_study_id>
    <nct_id>NCT04255836</nct_id>
  </id_info>
  <brief_title>Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Pilot Study of Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, multi-center pilot study assessing the efficacy and safety of durvalumab
      combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with
      oligo-metastatic non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-Free Survival (PFS) assessed according to RECIST 1.1 in subpopulation of patients with oligometastatic NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (AESI, AEs/SAEs)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the treat failure patterns</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Treat failure patterns including local failure and distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>ORR was defined as the proportion of participants with partial response (PR) or complete response (CR) to treatment as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and OS Overall Survival(OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>OS was defined as the time from the date of enrollment until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Durvalumab therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemo+Durvalumab (PD-L1 monoclonal antibody)1500 mg every 3 weeks [q3w] intravenously [iv] for 4 cycles, then SBRT 50-60 Gy/≤10f + Durvalumab 1500 mg q4w, then Durvalumab 1500 mg q4w for up to 24 months or until progression or other discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months</description>
    <arm_group_label>Durvalumab therapy</arm_group_label>
    <other_name>IMFINZI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>the first line chemotherapy for metastatic NSCLC</intervention_name>
    <description>paclitaxel+carboplatin or pemetrexed+cisplatin</description>
    <arm_group_label>Durvalumab therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiotherapy (SBRT)</intervention_name>
    <description>SBRT total doses of 50-60Gy/≤10F</description>
    <arm_group_label>Durvalumab therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer

          -  ≤3 metastatic organs and ≤5 metastatic lesions (supraclavicular and mediastinal lymph
             nodes are not classified as distant metastasis; other lymph node

          -  metastasis一group lymph node region will be classified as one metastatic lesion）

          -  Tissue biopsy prior to treatment

          -  ECOG performance score 0-1

        Exclusion Criteria:

          -  EGFR mutation or ALK positive.

          -  Evidence on pulmonary interstitial disease or symptoms of active non-infectious
             pneumonia.

          -  Active infection including tuberculosis, hepatitis B, hepatitis C, or human
             immunodeficiency virus.

          -  Previous treatment with antibody against pd -1, pd - L1, pd - L2, CD137 or CTLA-4
             (including ipilimumab or any antibody or drug against T cell co-stimulation or
             checkpoint pathway).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 2, 2020</last_update_submitted>
  <last_update_submitted_qc>February 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

